Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409509 · ClinicalTrials.gov registry record · Phase 2
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
A Phase 2 study of Coronavirus Disease 2019 (COVID-19), sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 14
- Study locations
NCT04409509: Completed Phase 2 study of Coronavirus Disease 2019 (COVID-19), sponsored by CSL Behring.
NCT04409509 is a Phase 2 study of Coronavirus Disease 2019 (COVID-19) that has completed, run by CSL Behring. The registered enrollment target is 124 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04409509, a Phase 2 study of Coronavirus Disease 2019 (COVID-19), has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
Study Locations (14)
Florida
- Nova Clinical Research, LLC - Bradenton
- Theia Clinical Research, LLC - St. Petersburg
Iowa
- MercyOne North Iowa Medical Center - Mason City
- Northeast Iowa Medical Education Foundation - Waterloo
New Jersey
- Holy Name Hospital - Teaneck
- Inspira Health Center Vineland - Vineland
Texas
- PharmaTex Research - Amarillo
- UT Health Science Center, McGovern Medical School - Houston
Massachusetts
- Lahey Hospital and Medical Center - Burlington
Mississippi
- University of Mississippi Medical Center - Jackson
New York
- Sisters of Charity Hospital/ St. Joseph's Campus - Buffalo
North Carolina
- Carolina Institute for Clinical Research - Fayetteville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2021-01-12 |
| Phase | Phase 2 |
What the finished NCT04409509 record still lists
NCT04409509 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Coronavirus Disease 2019 (COVID-19) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04409509 lists 14 locations in 10 states (Florida, Iowa, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04409509 about?
NCT04409509 is a clinical study titled "Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)". This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)
What is the current status of trial NCT04409509?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2020-07-01. Estimated completion is 2021-01-12.
What conditions does trial NCT04409509 study?
This clinical trial studies the following conditions: Coronavirus Disease 2019 (COVID-19).
What interventions are being tested in trial NCT04409509?
The interventions under investigation include: Placebo (DRUG), Garadacimab, Factor XIIa Antagonist Monoclonal Antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT04409509?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04409509 being conducted?
This trial has 14 study locations across Florida, Iowa, Massachusetts, Mississippi, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronavirus Disease 2019 (COVID-19)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04409509's enrollment target sits among peer trials
124 564th of 2000 higher than 1,437 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI